Volatile Movements: The Coca-Cola Co (NYSE:KO), Hartford Financial Services Group Inc (NYSE:HIG), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

On Tuesday,Shares of The Coca-Cola Co (NYSE:KO), subtract -0.45% and closed at $41.84 in the last trading session. The last trading range of the stock ranges between $41.78 and $42.34. Cycle for Survival, the movement to beat rare cancers, will welcome nearly 1,000 supporters to Times Square on September 30 for the fourth annual Times Square Takeover. This inspiring, all-day celebration will feature high-energy stationary cycling rides led by instructors from Equinox, Cycle for Survival’s founding partner. This year’s event is presented by smartwater®, Cycle for Survival’s longstanding official hydration sponsor.

Rare cancer survivors, patients and caregivers, Memorial Sloan Kettering doctors and special guests will ride together on more than 100 bikes in the heart of New York City to raise awareness about the fight to beat rare cancers.

2017 marks Cycle for Survival’s 11th year of indoor cycling rides. 100 percent of every dollar raised goes to rare cancer research led by Memorial Sloan Kettering, which owns and operates Cycle for Survival. Registration opened this month for the 2017 events taking place in 16 cities this February and March.

Hartford Financial Services Group Inc (NYSE:HIG), jumped 3.01% and closed at $43.78 in the last trading session. The last trading range of the stock ranges between $42.50 and $43.89. The company’s Market capitalization is $16.77 Billion with the total Outstanding Shares of 387.92 million. Two-time U.S. Paralympian Brad Snyder was named Male Athlete of the Paralympic Games, presented by The Hartford at the Team USA Awards presented by Dow, Best of the Games ceremony. Snyder won three gold medals and tied for silver at the Rio 2016 Paralympic Games. He defended his Paralympic titles in the 400- and 100-meter freestyle events, while breaking a 30-year-old world record in the 100 freestyle.

“Brad and Team USA’s amazing athletic performance demonstrated to the world that people are defined by their ability, not their physical limitations,” said Michael Concannon, executive vice president of Group Benefits at The Hartford. “We congratulate Brad and all of the U.S. Paralympic athletes who represented our country so successfully at this year’s Games.”

Stepped Down U.S. Navy Lt. Brad Snyder, who won a gold medal in swimming at the London 2012 Paralympic Games exactly one year after an explosion from an improvised explosive device (IED) in Afghanistan cost him his vision, is The Hartford’s national Paralympic ambassador this year. He has appeared in the company’s advertising and represented the insurer at events, counting South By Southwest, the annual film, music and technology festival in Austin, Texas. He and U.S. Paralympian Alana Nichols spoke on a panel about technology and disability and how prevailing is possible when you have the right resources and team behind you.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK), lost -1.32% and closed at $5.96 in the last trading session. The last trading range of the stock ranges between $5.91 and $6.22. During the 52-week trading session the minimum price at which share price traded, registered at $4.39 and reached to max level of $10.85. Merrimack Pharmaceuticals, Inc. (MACK) recently declared a major corporate restructuring with the objective of prioritizing its research and development on a focused set of systems biology-derived oncology products and strengthening its financial runway.  As part of this move, Merrimack is right away implementing a 22% reduction in headcount and eliminating more than $200 million in expected costs over the next two years. In line with this restructuring, the Board of Directors has accepted the resignation of President and CEO Robert Mulroy, effective right away.

In order to accelerate this change, the Board of Directors has designated Chairman of the Board Gary Crocker as interim President and CEO. “The Board is committed to focusing our resources. This major restructuring will allow us to plannedally align our pipeline with our core capabilities and prioritize ongoing clinical development efforts while improving our financial flexibility,” stated Mr. Crocker. “We believe this sharper focus will drive efficiency and innovation and promote the interests of not only our shareholders and employees, but also of cancer patients worldwide. The realization of shareholder value will become as intense a focus for Merrimack as our strength in innovation and development. The Board is convinced that there is tremendous inherent value within Merrimack that can be unlocked.”

Leave a Reply

Your email address will not be published. Required fields are marked *